Our comparative analysis in the FAHZZU melanoma cohort showed that patients who responded well to immunotherapy had higher MYO1G expression levels (Figure 6D), and those with elevated expression also exhibited longer progression-free survival (Figure 6E). The gene discussed is MYO1G; the disease is melanoma.